1. Home
  2. MRUS vs LBTYB Comparison

MRUS vs LBTYB Comparison

Compare MRUS & LBTYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRUS
  • LBTYB
  • Stock Information
  • Founded
  • MRUS 2003
  • LBTYB 2004
  • Country
  • MRUS Netherlands
  • LBTYB Bermuda
  • Employees
  • MRUS N/A
  • LBTYB N/A
  • Industry
  • MRUS Biotechnology: Pharmaceutical Preparations
  • LBTYB Cable & Other Pay Television Services
  • Sector
  • MRUS Health Care
  • LBTYB Telecommunications
  • Exchange
  • MRUS Nasdaq
  • LBTYB Nasdaq
  • Market Cap
  • MRUS 4.1B
  • LBTYB 4.2B
  • IPO Year
  • MRUS 2016
  • LBTYB N/A
  • Fundamental
  • Price
  • MRUS $67.47
  • LBTYB $12.22
  • Analyst Decision
  • MRUS Strong Buy
  • LBTYB
  • Analyst Count
  • MRUS 13
  • LBTYB 0
  • Target Price
  • MRUS $90.92
  • LBTYB N/A
  • AVG Volume (30 Days)
  • MRUS 550.9K
  • LBTYB 295.0
  • Earning Date
  • MRUS 10-30-2025
  • LBTYB 01-01-0001
  • Dividend Yield
  • MRUS N/A
  • LBTYB N/A
  • EPS Growth
  • MRUS N/A
  • LBTYB N/A
  • EPS
  • MRUS N/A
  • LBTYB N/A
  • Revenue
  • MRUS $56,228,000.00
  • LBTYB $4,633,000,000.00
  • Revenue This Year
  • MRUS $57.42
  • LBTYB $10.21
  • Revenue Next Year
  • MRUS $0.23
  • LBTYB $1.04
  • P/E Ratio
  • MRUS N/A
  • LBTYB N/A
  • Revenue Growth
  • MRUS 59.77
  • LBTYB 81.79
  • 52 Week Low
  • MRUS $33.19
  • LBTYB $9.15
  • 52 Week High
  • MRUS $69.20
  • LBTYB $21.90
  • Technical
  • Relative Strength Index (RSI)
  • MRUS 58.81
  • LBTYB 67.08
  • Support Level
  • MRUS $62.80
  • LBTYB $11.47
  • Resistance Level
  • MRUS $67.84
  • LBTYB $11.04
  • Average True Range (ATR)
  • MRUS 2.39
  • LBTYB 0.09
  • MACD
  • MRUS -0.22
  • LBTYB -0.04
  • Stochastic Oscillator
  • MRUS 73.67
  • LBTYB 86.72

About MRUS Merus N.V.

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

About LBTYB Liberty Global Ltd. Class B

Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.

Share on Social Networks: